Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
June 2011
Features
Drug Class Review
Protease Inhibitors for Patients With HIV-1 Infection
A Comparative Overview
Nine antiretroviral agents in the protease inhibitor class are discussed with an emphasis on their safety and efficacy.
Peter J. Hughes, PharmD; Erika Cretton-Scott, PhD; Ami Teague, PharmD, BCPS, AAHIVE; and Terri M. Wensel, PharmD, BCPS
Drug Class Review
The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection
The NNRTI class of medications has contributed significantly to the management of human immunodeficiency virus-1 (HIV-1) infection. Efavirenz (Sustiva), nevirapine (Viramune), etravirine (Intelence), and the newest FDA-approved agent, rilpivirine (Edurant), all have potential benefits when used in appropriate patients.
Jason J. Schafer, PharmD, BCPS, AAHIVE; Saranyu Ravi, PharmD Candidate; Evelyn V. Rowland, PharmD Candidate; Germin Shenoda, PharmD Candidate;
and Nicholas Leon, PharmD, BCPS
Meeting Highlights
Digestive Disease Week 2011
Sessions cover studies of clopidogrel use in colonoscopy, rifaximin in preventing spontaneous bacterial peritonitis, the effects of teduglutide use in short-bowel syndrome and parenteral nutrition, and the link between Clostridium difficile infection and antibiotics.
Walter Alexander
Pharmaceutical Approval Update
Abiraterone (Zytiga) for advanced prostate cancer, linagliptin (Tradjenta) for glycemic control, and peginterferon alfa-2b (Sylatron) for melanoma
Marvin M. Goldenberg, PhD, RPh, MS
P&T Snapshot
A Survey on Managing Multiple Sclerosis
The Managed Care Perspective
In an effort to control the cost of treating patients with multiple sclerosis, many health plans have introduced restraints such as requiring prior authorization, restricting the use of the drugs to FDA-approved indications, limiting the quantity of drugs that may be prescribed, and setting dosage limits.
Mari Edlin and Peter Sonnenreich, MA
Departments
Medication Errors
Fluorouracil Mistake Ends With a Fatality
Applying the Lessons Learned Can Save Lives
With fluorouracil, hours can seem like days.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
New Medicare Part D Rule Affects Long-Term-Care Pharmacies
Medicare Part D: a chain of changes for long-term-care pharmacies and nursing homes
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Drug Forecast
Ulipristal Acetate (ella)
A Selective Progesterone Receptor Modulator For Emergency Contraception
Ulipristal acetate (ella) for emergency contraception
Andrea Kim, PharmD Candidate; and Mary Barna Bridgeman, PharmD, BCPS
